Literature DB >> 16447148

Investigation of vancomycin and related substances by liquid chromatography/ion trap mass spectrometry.

J Diana1, D Visky, J Hoogmartens, A Van Schepdael, E Adams.   

Abstract

Liquid chromatography (LC) methods compatible with mass spectrometry (MS) that are suitable for impurity profiling of vancomycin mixtures have not been described in the literature. The mobile phases of the existing methods contain non-volatile additives and/or solvents that give problems in combination with MS. In this paper, a reversed-phase LC/tandem mass spectrometry method is described for the investigation of vancomycin and related substances. The LC method uses a Zorbax Extend C18 column (250 x 4.6 mm i.d.), 5 microm, and a mobile phase consisting of methanol, water and ammonium acetate solution (pH 9.0). This method allows us to separate vancomycin and its impurities. Mass spectral data are acquired on an LCQ ion trap mass spectrometer equipped with an electrospray interface operated in the positive and negative ion modes. The LCQ is ideally suited for identification of impurities and related substances because it provides on-line LC/MSn capability, which allows efficient identification without time-consuming isolation and purification procedures. Using this method, the fragmentation of vancomycin and known derivatives was studied and the structures of six substances occurring in commercial samples were elucidated. Copyright 2006 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16447148     DOI: 10.1002/rcm.2364

Source DB:  PubMed          Journal:  Rapid Commun Mass Spectrom        ISSN: 0951-4198            Impact factor:   2.419


  5 in total

1.  Product quality of parenteral vancomycin products in the United States.

Authors:  S Nambiar; R D Madurawe; S M Zuk; S R Khan; C D Ellison; P J Faustino; D J Mans; M L Trehy; M E Hadwiger; M T Boyne; K Biswas; E M Cox
Journal:  Antimicrob Agents Chemother       Date:  2012-02-06       Impact factor: 5.191

2.  Quality assessment of U.S. marketplace vancomycin for injection products using high-resolution liquid chromatography-mass spectrometry and potency assays.

Authors:  Michael E Hadwiger; Cynthia D Sommers; Daniel J Mans; Vikram Patel; Michael T Boyne
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

3.  Three structurally-related impurities in norvancomycin drug substance.

Authors:  Zhibo Jiang; Xuan Lei; Minghua Chen; Bingya Jiang; Linzhuan Wu; Xuexia Zhang; Zhihui Zheng; Xinxin Hu; Xuefu You; Shuyi Si; Lifei Wang; Bin Hong
Journal:  J Antibiot (Tokyo)       Date:  2016-10-05       Impact factor: 2.649

4.  Implementation of a single quad MS detector in routine QC analysis of peptide drugs.

Authors:  Matthias D'Hondt; Bert Gevaert; Evelien Wynendaele; Bart De Spiegeleer
Journal:  J Pharm Anal       Date:  2015-09-26

5.  Polymerizable vancomycin derivatives for bactericidal biomaterial surface modification: structure-function evaluation.

Authors:  McKinley C Lawson; Richard Shoemaker; Kevin B Hoth; Christopher N Bowman; Kristi S Anseth
Journal:  Biomacromolecules       Date:  2009-08-10       Impact factor: 6.988

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.